AnalizaDx, LLC is a cancer diagnostics company that has developed and is presently commercializing a proprietary platform technology to improve cancer detection, diagnosis, progression and prognosis.
A spin-off company from Analiza, Inc., AnalizaDx's cancer detection technology differs from conventional biomarker technologies that measure the amount of a disease-related protein, as it identifies biomarkers based on changes in their structure. Significant advantages of this type of detection include the use of readily available biological fluids, insensitivity to the significant variations in the absolute amount of biomarkers that naturally occur from patient to patient and the ability to make screening and diagnosis affordable by utilizing existing, standard lab equipment.
The company has successfully completed clinical studies for prostate, breast and ovarian cancers, is presently performing advanced multi-site clinical studies and is putting together collaborations for early commercialization of its first test to market.
Initial JumpStart Investment: October 2006
For more information on AnalizaDx, contact: Lynn-Ann Gries